Novo Nordisk Invests $4.1B in Clayton, NC Plant

In Clayton, North Carolina, US, Novo Nordisk is building a new aseptic and finished product production plant. On the Clayton campus, it will be the company's second fill-and-finish facility.The new facility, which was announced in June 2024, would increase the company's ability to develop injectable medications for obesity and other severe chronic conditions, both now and in the future.

Novo Nordisk is funding the new plant with $4.1 billion. The initiative is a component of Novo Nordisk's intentions to grow its present investments in 2024, with a goal of contributing $6.8 billion to production, a substantial increase from the $3.9 billion invested the year before.The facility's foundation and preliminary clearance work have started, and development will be finished gradually between 2027 and 2029. 2,000 outside contractors are anticipated to work on the project during its busiest building period.

A further 1,000 jobs will be created by the new plant, bringing the total number of Novo Nordisk employees in the area to 2,500.The new plant, which would occupy 56 acres (22.7 hectares) on the Novo Nordisk property in Clayton, North Carolina, will be located there. The total square footage of the company's three current North Carolina locations will be doubled.